Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical, Inc. (ISRG) closed at $293.51 in the latest trading session, marking a +1.78% move from the prior day.

Intuitive Surgical, Inc. (ISRG) Gains But Lags Market: What You Should Know

Boston Scientific

The decline from September 2021 in Medical Device stocks was healthy. Similar price structures provide confidence in coming upside.

Riding The Stock Waves: Update On The Medical Devices Sector

We think Intuitive Surgical stock is currently a better pick than Roper Technologies stock, a software, engineered products, and solutions provider, with a similar revenue base as Intuitive Surgical, despite Intuitive Surgical's comparatively higher valuation. ISRG stock trades at about 18x.

Here's Why Intuitive Surgical Stock Is A Better Pick Over This Software Company

Costco

Estee Lauder

Big winner stocks are elusive but if you can find one, it can transform your portfolio.

How to Find Lottery Stocks

Etsy

T. Rowe Price Group

If you're a fan of bargains, there are plenty of names worth a look left behind in the wake of the market's recent pullback.

3 Poor-Performing Nasdaq Stocks Ready To Bounce Back Big Time

Colgate-Palmolive

Walgreens

Healthcare stocks come in all shapes and sizes, and can be long-term assets in your portfolio.

3 Top Stocks to Buy in February and Hold Forever

Earnings are expected to decline in 2022 as COVID resurgences hurt.

Bear of the Day: Intuitive Surgical (ISRG)

This company is revolutionizing the field of surgical robotics.

This Healthcare Stock Has Huge Upside Potential

Alphabet

NVIDIA

These stocks are poised for long-term success regardless of how this year unfolds.

3 Unstoppable Stocks to Buy No Matter What Happens in 2022

COVID-19 has slowed down growth, but long-term prospects look very promising.

Why Intuitive Surgical's Share Slump Is a Gift for Investors

Alignment Healthcare

Anthem

CVS Health

Could health care stocks be back in focus amid market volatility?

Top 4 Health Care Stocks To Watch In February 2022

Beyond Meat

While they are slightly pricey now, these stocks have some incredible growth potential.

2 Growth Stocks to Buy if There's a Market Crash

Curaleaf Holdings, Inc.

Pinterest

A well-balanced diversified portfolio is fruitful in the long run.

3 Best Unstoppable Stocks to Own in 2022

Edwards Lifesciences

Stryker

"I think there are some true steals are developing in the medical device space because of omicron," the "Mad Money" host said.

Jim Cramer says these three medical device stocks look like 'true steals' here

Zscaler

Activision Blizzard

Microsoft

Macroeconomic conditions have shocked the market thus far in 2022. While some investors are running for the hills, others are looking for opportunities.

4 Stocks To Buy The Dip - Zscaler, Microsoft And More

Bank of America

Palo Alto Networks

Palantir Technologies

Big down days are an opportunity for patient investors to buy great companies at a discount.

5 Surefire Stocks to Buy During This Stock Market Correction

The medical device maker reported another solid quarter.

Why Intuitive Surgical Keeps Growing and Growing

Intuitive Surgical reported its Q4 results last week, with revenue above, but earnings falling short of our estimates. The company reported revenue of $1.55 billion (up 17% y-o-y), marginally above our forecast of $1.53 billion and the consensus estimate of $1.52 billion.

Intuitive Surgical Stock Looks Attractive After Its Recent Fall

Bath and Body Works

Netflix

Investors looking to buy the dip should consider companies that have been hit hardest but still have solid long-term growth prospects. It is here that valuations have become more reasonable and entry points more attractive.

3 S&P 500 Laggards To Buy On the Dip

Berkshire Grey

Luminar Technologies

Ouster, Inc

Vicarious Surgical

Titan Medical Inc

Trimble

Velodyne Lidar

Zebra Technologies

December 2021 saw investments in robotics of roughly USD1.2bn. The lion's share of the funding in went to autonomous driving companies.

Robotics Investments In December 2021

Surgical robotics is increasingly being adopted by doctors and patients, and the market is expected to rapidly expand by 19.3% over the next several years. ISRG is extremely profitable, with profit margins around 70%, and a cash balance that has increased $1.7 B over fiscal 2021.

Intuitive Surgical: Market Leader In Robotic Surgery

It wasn't all about the streaming company.

These 2 Nasdaq Stocks Are Falling Despite Better Results Than Netflix

This isn't how earnings beats are supposed to work.

Why Intuitive Surgical Stock Just Dropped

Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.

Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates

A Citigroup analyst believes the pullback in shares of Intuitive Surgical is a buying opportunity.

News for Intuitive Surgical Stock (ISRG)